Pre-application for the NIH-Industry Program: Discovering New Therapeutic Uses for Existing Molecules (X02)Funding Number: PAR-14-213
Release Date: May 12, 2014
Expiration Date: July 16, 2014
Web Site: http://grants.nih.gov/grants/guide/pa-files/PAR-14-213.html
The National Center for Advancing Translational Sciences (NCATS) seeks to expand the therapeutics discovery program piloted in 2012, to explore new therapeutic uses for proprietary drug candidates (Agents) across a broad range of human diseases. This innovative program allows investigators to propose new therapeutic uses for Agents from pharmaceutical company partners. A strong application will be supported by scientific evidence that modulation of the Agents target will have a positive impact on the disease/condition. PAR-14-213 encourages X02 pre-applications for the NIH-Industry Program: Discovering New Therapeutic Uses for Existing Molecules.The X02 pre-application is the first step in the application process for PAR-14-212, PAR-14-211 and PAR-14-210; applicants must read all of the companion FOAs. The X02 pre-applications will be evaluated by outside experts. Investigators whose X02 pre-applications are judged to be the most meritorious will be notified of the opportunity to submit a UH2/UH3 under PAR-14-212 or a UH3 application under PAR-14-211 or a UH2/UH3 application under PAR-14-210 in the case of a pediatric indication.